Gemcitabine Hydrochloride Injection, Powder, Lyophilized, For Solution
Product Images NDC 82511-009

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Gemcitabine Hydrochloride (NDC 82511-009). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Teyro Labs Private Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image Description (Gemcitabine Hydrochloride 1g Carton Label)

Packaging label for Gemcitabine hydrochloride 1 g/vial injection, lyophilized powder for solution, USP. The label indicates it is for intravenous use only, sterile single-dose vial, and cautions it as a cytotoxic agent. Manufactured by Teyro Labs Private Limited, India, with storage instructions and reconstitution details included. The NDC number 82511-009-10 is shown.*

FDA Label Image

Image Description (Gemcitabine Hydrochloride 1g Vial Label)

Label for Gemcitabine hydrochloride injection, powder, lyophilized, 1 g per vial by Teyro Labs Private Limited. The label states it is for intravenous use only, single-dose vial, and includes handling instructions, storage conditions, and a caution that the product is a cytotoxic agent.*

FDA Label Image

Image Description (Gemcitabine Hydrochloride 200mg Carton Label)

Label for Gemcitabine hydrochloride injection, USP 200 mg per vial, lyophilized powder for intravenous use. The label specifies it is a sterile single-dose vial and highlights that it is a cytotoxic agent. Manufacturer is Teyro Labs Private Limited, India. Storage instructions and directions for reconstituting with 5 mL of 0.9% Sodium Chloride Injection are included.*

FDA Label Image

Image Description (Gemcitabine Hydrochloride 200mg Vial Label)

Label for Gemcitabine hydrochloride injection, USP, 200 mg per vial, lyophilized powder for solution for intravenous use. It is a sterile single-dose vial manufactured by Teyro Labs Private Limited. The label includes storage instructions, reconstitution directions, and cautions indicating it is a cytotoxic agent. Barcode and revision date 08/2024 are visible.*

FDA Label Image

Image Description (Gemcitabine Hydrochloride Graph 1)

A Kaplan-Meier curve chart showing progression-free survival probability over time (months) for two groups: Gemzar/Carboplatin (N=178) and Carboplatin alone (N=178). The Gemzar/Carboplatin group shows a higher progression-free probability, with a median progression-free survival of 8.6 months compared to 5.8 months for Carboplatin alone, accompanied by a log-rank p-value of 0.0038.*

FDA Label Image

Image Description (Gemcitabine Hydrochloride Graph 2)

A Kaplan-Meier survival curve chart showing progression-free probability over time until documented disease progression in months for two treatment groups: Gemzar/Paclitaxel and Paclitaxel alone. The chart compares progression-free survival for 267 patients on Gemzar/Paclitaxel and 262 patients on Paclitaxel, indicating median times to progression of 5.2 and 2.9 months respectively, with a log-rank p-value less than 0.0001.*

FDA Label Image

Image Description (Gemcitabine Hydrochloride Graph 3)

A Kaplan-Meier survival curve graph comparing survival probability over time (months) between two treatment groups: Gemcitabine/Cisplatin and Cisplatin alone. The graph shows median survival of 9.0 months for Gemcitabine/Cisplatin and 7.6 months for Cisplatin, with corresponding 1-year survival rates of 39% and 28%, respectively. The graph also includes Logrank and Wilcoxon test statistics with p-values indicating statistical significance.*

FDA Label Image

Image Description (Gemcitabine Hydrochloride Graph 4)

A survival curve graph comparing the fraction of surviving subjects over time in months for Gemzar and 5-FU treatments. The y-axis represents the fraction surviving from 0.0 to 1.0, and the x-axis represents survival time in months up to 20. The curve for Gemzar shows a higher survival fraction over time compared to 5-FU.*

FDA Label Image

Image Description (Gemcitabine Hydrochloride Structure)

Chemical structure of gemcitabine hydrochloride, a nucleoside analog used as an anticancer agent. The diagram shows its molecular framework including hydroxyl groups, fluorine atoms, a pyrimidine ring, and the hydrochloride group.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.